KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Change in Receivables (2020 - 2025)

Boston Scientific's Change in Receivables history spans 6 years, with the latest figure at $98.0 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 8.89% year-over-year to $98.0 million; the TTM value through Dec 2025 reached $269.0 million, down 23.36%, while the annual FY2025 figure was $269.0 million, 23.36% down from the prior year.
  • Change in Receivables for Q4 2025 was $98.0 million at Boston Scientific, up from $32.0 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $148.0 million in Q4 2021 and bottomed at -$14.0 million in Q3 2021.
  • The 5-year median for Change in Receivables is $74.5 million (2023), against an average of $67.8 million.
  • The largest annual shift saw Change in Receivables crashed 111.38% in 2021 before it surged 1000.0% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $148.0 million in 2021, then tumbled by 70.27% to $44.0 million in 2022, then surged by 68.18% to $74.0 million in 2023, then rose by 21.62% to $90.0 million in 2024, then grew by 8.89% to $98.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's Change in Receivables are $98.0 million (Q4 2025), $32.0 million (Q3 2025), and $32.0 million (Q2 2025).